Antibe Therapeutics Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported net loss was CAD 19.48 million compared to CAD 25.06 million a year ago. Basic loss per share was CAD 0.37 compared to CAD 0.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 CAD | -.--% | -.--% | -68.28% |
24/04 | Antibe Therapeutics Inc. Announces Board Resignations | CI |
19/04 | Antibe Therapeutics Seeks Extension of Stay of Proceedings | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.28% | 1.14Cr | |
+3.91% | 11TCr | |
+10.87% | 11TCr | |
-0.26% | 2.23TCr | |
-13.14% | 2.21TCr | |
-8.05% | 1.87TCr | |
-38.36% | 1.76TCr | |
-10.66% | 1.69TCr | |
+3.75% | 1.38TCr | |
+36.70% | 1.25TCr |
- Stock Market
- Equities
- ATE Stock
- News Antibe Therapeutics Inc.
- Antibe Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023